Inštitucionálne vlastníctvo spoločnosti Novabay Pharmaceuticals Inc

Aká je hodnota metriky Inštitucionálne vlastníctvo spoločnosti Novabay Pharmaceuticals Inc?

Hodnota metriky Inštitucionálne vlastníctvo spoločnosti Novabay Pharmaceuticals Inc je 2.57%

Aká je definícia metriky Inštitucionálne vlastníctvo?



Inštitucionálne vlastníctvo (Institutional Ownership) je množstvo akcií spoločnosti vlastených podielovými alebo penzijnými fondami, poisťovňami, investičnými firmami, a ďalšími entitami, ktoré spravujú peňažné prostriedky iných.

Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.

Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.

Inštitucionálne vlastníctvo spoločností v sektore Health Care sektor na NYSEMKT v porovnaní so spoločnosťou Novabay Pharmaceuticals Inc

Čomu sa venuje spoločnosť Novabay Pharmaceuticals Inc?

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across

Firmy s metrikou inštitucionálne vlastníctvo podobnou spoločnosti Novabay Pharmaceuticals Inc